Therefore, our results seem to further support the use of ICIs in vulvar cancer treatment and, as reported in the KEYNOTE-826 trial for cervical cancer patients, the presence of PD-L1 expression could influence the response to treatment; in any case, this remains an hypothesis to be confirmed in specific clinical trials on VSCC patients. The gene discussed is CD274; the disease is vulva cancer.